
November 20, 2017 - By Louis Casey
Honeywell International Inc decreased Bristol Myers Squibb Co (BMY) stake by 66.96% reported in 2017Q2 SEC filing. Honeywell International Inc sold 440,000 shares as Bristol Myers Squibb Co (BMY)’s stock

Sustainable Growth Advisers Lp decreased Novo Nordisk A/S (NVO) stake by 13.93% reported in 2017Q2 SEC filing. Sustainable Growth Advisers Lp sold 566,618 shares as Novo Nordisk A/S (NVO)’s stock rose 15.20%. The Sustainable Growth Advisers Lp holds 3.50M shares with $150.21M value, down from 4.07M last quarter. Novo Nordisk A/S now has $101.08 billion valuation. The stock rose 1.28% or $0.65 reaching $51.56. About 222,361 shares traded. Novo Nordisk A S (ADR) (NYSE:NVO) has declined 23.93% since November 20, 2016 and is downtrending. It has underperformed by 40.63% the S&P500.Analysts await Novo Nordisk A S (ADR) (NYSE:NVO) to report earnings on February, 1. They expect $0.56 EPS, up 12.00% or $0.06 from last year’s $0.5 per share. NVO’s profit will be $1.10B for 23.02 P/E if the $0.56 EPS becomes a reality. After $0.62 actual EPS reported by Novo Nordisk A S (ADR) for the previous quarter, Wall Street now forecasts -9.68% negative EPS growth. Among 13 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 4 have Buy rating, 0 Sell and 9 Hold. Therefore 31% are positive. Novo Nordisk (ADR) had 15 analyst reports since August 28, 2015 according to SRatingsIntel. The company was downgraded on Friday, October 28 by Bank of America. The company was downgraded on Monday, October 31 by Citigroup. As per Friday, September 9, the company rating was downgraded by JP Morgan. The rating was upgraded by UBS on Tuesday, December 6 to “Buy”. As per Friday, September 23, the company rating was initiated by Piper Jaffray. On Wednesday, September 6 the stock rating was upgraded by Bank of America to “Neutral”. BNP Paribas upgraded the stock to “Outperform” rating in Tuesday, September 13 report. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) earned “Hold” rating by Zacks on Friday, August 28. On Monday, October 19 the stock rating was upgraded by Jyske Bank to “Strong Buy”. The stock of Novo Nordisk A S (ADR) (NYSE:NVO) earned “Sell” rating by UBS on Monday, February 8.Sustainable Growth Advisers Lp increased Automatic Data Processing Inc (NASDAQ:ADP) stake by 57,956 shares to 1.64M valued at $167.72 million in 2017Q2. It also upped Starbucks Corp (NASDAQ:SBUX) stake by 48,151 shares and now owns 2.84 million shares. Alphabet Inc Cl C was raised too. Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 68 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Thursday, October 19 with “Hold”. As per Monday, October 23, the company rating was maintained by Leerink Swann. Deutsche Bank maintained the stock with “Hold” rating in Monday, July 17 report. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Buy” rating by Jefferies on Monday, July 17. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Buy” rating given on Friday, April 29 by UBS. Morgan Stanley downgraded Bristol-Myers Squibb Co (NYSE:BMY) on Friday, August 5 to “Equal-Weight” rating. On Thursday, August 11 the stock rating was downgraded by Berenberg to “Hold”. The rating was initiated by Hilliard Lyons with “Neutral” on Monday, May 23. The rating was maintained by Piper Jaffray on Friday, September 22 with “Hold”. The company was maintained on Friday, April 29 by Barclays Capital.Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on January, 25. They expect $0.67 EPS, up 6.35% or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10B for 22.63 P/E if the $0.67 EPS becomes a reality. After $0.75 actual EPS reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -10.67% negative EPS growth. By Louis CaseyEchostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.